Merck expands CRISPR patent portfolio

12-05-2020

Rory O'Neill

Merck expands CRISPR patent portfolio

Juriaan Wossink / shutterstock.com

Merck has added two US patents to its CRISPR-Cas9 patent portfolio, and is already seeking licensing and product development partners, the German company announced yesterday, May 11.


Merck, CRISPR-Cas9, patents, portfolio, US, University of California, Broad Institute, USPTO, IP, gene-editing

LSIPR